SenzaGen obtains OECD approval for GARD®skin


SenzaGen today announced that the Company has obtained approval from the OECD for GARD®skin as a test guideline for non-animal skin sensitization. This means that customers in all OECD member countries can now use GARD®skin test results for regulatory filings, which creates excellent prospects and opens up vast potential for sales growth for SenzaGen. The test is the first and only non-animal OECD-approved test for assessing the allergenicity of chemicals based on genomics and machine learning.

The Organisation for Economic Co-operation and Development (OECD) today published its approval of SenzaGen’s non-animal skin sensitization test, GARD®skin, as a part of Test Guideline 442E In vitro Skin Sensitization. An OECD test guideline enables customers in industries including cosmetics and chemicals in the EU, US and parts of Asia to use GARD®skin test results for regulatory filings. The approval gives the Company access to the entire non-animal toxicology market for skin sensitization.

“The OECD decision is a regulatory breakthrough for our GARD® technology. With OECD approval in place, we can offer the GARD®skin test to a much broader group of customers, which will result in greater demand for the test, and we expect increased sales volumes in the future. GARD®skin is a high-performance and highly reliable method with a broad application area, especially because it is very well suited for use with chemicals that are traditionally considered difficult to assess. This is an area in which we hold a unique industry position. SenzaGen is the first company in the world to develop and apply new technology based on genomics and machine learning to the field of toxicology and skin sensitization, which will lead to results that are better and safer for humans,” says Peter Nählstedt, President and CEO of SenzaGen.

GARD®skin meets a unique customer need

With high reliability, GARD®skin test results help product development companies and producers ensure that the products they bring to market are free of allergies, enabling them to prove this in their regulatory filings. This is the first test to give customers the capability to test chemicals traditionally considered difficult to test. As a result, GARD®skin meets a need in skin sensitization not covered by any other available tests.

The OECD approval

The OECD’s applicable regulatory testing strategy for non-animal skin sensitization includes chemical assessment with several parameters. For skin sensitization assessment, GARD®skin is accepted as a stand-alone method for positive results and together with additional evidence for negative results.

The OECD’s official announcement on the adoption of GARD®skin as a test guideline for non-animal skin sensitization is available on the following web page:

Web conference

SenzaGen invites the media and investors to a web conference on July 5 at 14.00 CEST at which CEO Peter Nählstedt will provide a briefing on the OECD approval. The web conference will be held in English starting with a presentation followed by a Q&A session.


Phone number for the conference

To participate in the conference call, use the dial-in numbers below.

SE: +46 856642651

UK: +44 3333000804

NE: +31 207095189

FR: +33 170750711

DE: +496913803430

CH: +41 225809034

Pin code: 65480307#

After the live broadcast, the web conference will be available on the Company’s website.


Peter Nählstedt, President and CEO, SenzaGen AB

Email: | Mobile: +46 700 23 44 31

Tina Dackemark Lawesson, VP Marketing & Communications

Email: | Mobile: +46 708 20 29 44

About us

SenzaGen aims to be a leader in in vitro science and testing, driving the transition from animal testing to methods better suited to reflect human biology. The Company provides high-performance, non-animal test methods and innovation and consulting services based on state-of-the-art technology. Non-animal methods are more effective, more accurate and less expensive than traditional animal-based methods while also helping to reduce the number of laboratory animals. The Company has a growth strategy centered around continued commercialization of its proprietary GARD® test platform, expansion of its test portfolio and evaluation of acquisition opportunities of profitable and growing companies with complementary offerings. SenzaGen has its headquarters and GLP-certified laboratory in Lund, Sweden and subsidiaries in the US and Italy. For more information, please visit:

SenzaGen is listed on Nasdaq Stockholm First North (ticker: SENZA), and FNCA Sweden AB, +46(0)8-528 00 399,, is the company’s Certified Adviser.